General tissue inflammatory markers
Mepolizumab reduced the proportion of patients with moderate or severe tissue inflammation (100% vs 68%, p=0.031) and subepithelial oedema (100% vs 63%, p=0.016) from baseline at treatment conclusion (Table 2). Mepolizumab did not change the following histopathological outcomes in sinonasal tissue from baseline at Week 24: neutrophils, inflammatory predominance, basement membrane thickening, hyperplastic papillary change, mucosal ulceration, squamous metaplasia and fibrosis.